Catalog #CP108
RecombiMAb anti-mouse/human/canine HER2 (domain III) (CD340)
Clone
H2Mab-19-CP108
Reactivities
Mouse, Human, Canine
Isotype
Mouse IgG2a, kappa
(switched from Mouse IgG2b, kappa)
(switched from Mouse IgG2b, kappa)
You may also be interested in:
Product Description
The H2Mab-19-CP108 monoclonal antibody is a recombinant, Fc-engineered chimeric version of the original H2Mab-19 antibody. The variable domain sequences are identical but the constant region sequences have been switched from Mouse IgG2b, κ to Mouse IgG2a, κ. Effector functions significantly enhance the efficacy of anti-HER2 antibodies by enabling antibody‑dependent cellular cytotoxicity (ADCC), phagocytosis (ADCP), complement‑dependent cytotoxicity (CDC) and opsonization to promote immune-mediated tumor clearance beyond HER2 signaling blockade alone. Mouse IgG2a has broader and higher-affinity interactions with activating FcγRs than mouse IgG2b, resulting in increased effector functions. The highly controlled sequence and lack of genetic drift in recombinant antibodies provide more reliable and reproducible results over hybridoma derived antibodies.
The H2Mab-19 monoclonal antibody reacts with domain III of mouse, human and canine receptor tyrosine-protein kinase erbB-2 (ERBB2), also known as human epidermal growth factor receptor 2 (HER2), CD340, or NEU. HER2 is a 185 kDa transmembrane receptor tyrosine kinase that is part of the EGFR family. The HER2 receptor contains a cytoplasmic tyrosine kinase domain, multiple cytoplasmic tyrosine residues that function as phosphorylation sites, a hydrophobic single-pass transmembrane domain, and an extensive extracellular domain (ECD) subdivided into four functional domains (I, II, III, and IV). Domains I and III facilitate ligand binding, domain II reinforces protein-protein interactions during dimerization, and domain IV stabilizes interactions between HER2 and its dimerization partner. HER2 lacks identified ligands; nonetheless, its homodimerization (HER2/HER2) and heterodimerization (EGFR/HER2, HER2/HER3, and HER2/HER4) facilitate HER2 activation, subsequently modulating downstream signaling pathways, including PI3K/Akt/mTOR and NF-kB. HER2 is essential for cell proliferation, survival, and differentiation, and in cancers, dysregulated HER2 signaling or its overexpression often correlates with aggressive tumor growth. In addition to breast cancer, HER2 is overexpressed in gastric, gastroesophageal, colorectal, lung, endometrial, and ovarian cancers. The H2Mab-19 antibody has been shown to have anti-tumor activity in HER2+ xenograft models.
The H2Mab-19 monoclonal antibody reacts with domain III of mouse, human and canine receptor tyrosine-protein kinase erbB-2 (ERBB2), also known as human epidermal growth factor receptor 2 (HER2), CD340, or NEU. HER2 is a 185 kDa transmembrane receptor tyrosine kinase that is part of the EGFR family. The HER2 receptor contains a cytoplasmic tyrosine kinase domain, multiple cytoplasmic tyrosine residues that function as phosphorylation sites, a hydrophobic single-pass transmembrane domain, and an extensive extracellular domain (ECD) subdivided into four functional domains (I, II, III, and IV). Domains I and III facilitate ligand binding, domain II reinforces protein-protein interactions during dimerization, and domain IV stabilizes interactions between HER2 and its dimerization partner. HER2 lacks identified ligands; nonetheless, its homodimerization (HER2/HER2) and heterodimerization (EGFR/HER2, HER2/HER3, and HER2/HER4) facilitate HER2 activation, subsequently modulating downstream signaling pathways, including PI3K/Akt/mTOR and NF-kB. HER2 is essential for cell proliferation, survival, and differentiation, and in cancers, dysregulated HER2 signaling or its overexpression often correlates with aggressive tumor growth. In addition to breast cancer, HER2 is overexpressed in gastric, gastroesophageal, colorectal, lung, endometrial, and ovarian cancers. The H2Mab-19 antibody has been shown to have anti-tumor activity in HER2+ xenograft models.
Specifications
| Isotype | Mouse IgG2a, κ |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb mouse IgG2a isotype control, unknown specificity |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Immunogen | Recombinant human HER2 extracellular domain |
| Reported Applications |
Flow cytometry ELISA in vivo antitumor activity in HER2+ models* in vitro induction of ADCC in HER2+ cells* in vitro induction of CDC in HER2+ cells* Immunohistochemistry (frozen)* *Reported for clone H2Mab-19. For information on in vivo applications, please contact technicalservice@bioxcell.com |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL assay |
| Aggregation* |
<5% Determined by SEC |
| Purity |
≥95% Determined by SDS-PAGE |
| Sterility | 0.2 µm filtration |
| Production | Purified from mammalian cell supernatant in an animal-free facility |
| Molecular Weight | 150 kDa |
| Murine Pathogen Tests |
Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| Need a Custom Formulation? | See All Antibody Customization Options |
* Additional quality control measures for our InVivoPlusâ„¢ products include advanced binding validation, murine pathogen screening, protein aggregation screening, and ultra-low endotoxin levels. The superior quality of our InVivoPlusâ„¢ products will meet and exceed the strict demands and rigorous standards required for in vivo research. Learn more about the InVivoPlusâ„¢ difference here.